Aurora breast MRI system available with SprialRodeo
Aurora Imaging Technology showcased its Aurora 1.5T dedicated breast MRI system bundled with SprialRodeo technology. The advanced imaging modality is designed specifically for bilateral 3D breast imaging and provides full coverage of the breasts, chest wall and axillae in a single scan.
SpiralRodeo increases resolution of breast MRI images without compromising temporal resolution. The improved acquisition efficiency (three times greater than traditional 3D Fourier Transform reconstruction) increases resolution of images and decreases scanning time. The images offer signal improvement comparable with that of a 4.5T system, the company said.
As a diagnostic imaging tool, the Aurora 1.5T dedicated breast MRI system with bilateral SpiralRodeo is ideal for a wide range of indications in breast disease management including: detecting or excluding the existence of cancer in higher risk women; characterizing indeterminate clinical or mammographically detected abnormalities; determining the extent of cancer for treatment planning; detecting occult cancer; evaluating patients for residual disease following surgery; monitoring cancer response and the extent of residual disease after chemotherapy; and evaluating implant integrity and detecting cancer in women with breast augmentation.
SpiralRodeo increases resolution of breast MRI images without compromising temporal resolution. The improved acquisition efficiency (three times greater than traditional 3D Fourier Transform reconstruction) increases resolution of images and decreases scanning time. The images offer signal improvement comparable with that of a 4.5T system, the company said.
As a diagnostic imaging tool, the Aurora 1.5T dedicated breast MRI system with bilateral SpiralRodeo is ideal for a wide range of indications in breast disease management including: detecting or excluding the existence of cancer in higher risk women; characterizing indeterminate clinical or mammographically detected abnormalities; determining the extent of cancer for treatment planning; detecting occult cancer; evaluating patients for residual disease following surgery; monitoring cancer response and the extent of residual disease after chemotherapy; and evaluating implant integrity and detecting cancer in women with breast augmentation.